Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTOReTAK: infliximab versus tocilizumab in refractory or relapsing Takayasu arteritis
2024-512229-10-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Takayasu arteritis (TAK) comparing Infliximab arm with Tocilizumab arm (2 arms). Primary endpoint: Sustained inactive disease with low-dose prednisone at 6 months. Planned start Sep 2024; status: authorised.
02
Drugs
infliximabtocilizumab
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on 2024-512229-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512229-10-00.